Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback